Financhill
Buy
52

BLFS Quote, Financials, Valuation and Earnings

Last price:
$24.93
Seasonality move :
6.09%
Day range:
$24.86 - $25.39
52-week range:
$19.10 - $29.62
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.92x
P/B ratio:
3.39x
Volume:
186.3K
Avg. volume:
359.8K
1-year change:
-7.88%
Market cap:
$1.2B
Revenue:
$82.3M
EPS (TTM):
-$0.07

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BLFS
BioLife Solutions, Inc.
$25.6M $0.00 5.9% -98.07% $32.10
DXCM
DexCom, Inc.
$1.2B $0.47 11.43% 70.31% $85.27
IVF
INVO Fertility, Inc.
$1.8M -- -8.8% -- --
NMTC
NeuroOne Medical Technologies Corp.
$2.2M -- -54.48% -57.14% $2.23
NTRB
Nutriband, Inc.
$765K -$0.17 4.52% -54.85% $15.00
SINT
SINTX Technologies, Inc.
$400K -$0.54 -44.65% -56.43% $12.25
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BLFS
BioLife Solutions, Inc.
$24.90 $32.10 $1.2B -- $0.00 0% 11.92x
DXCM
DexCom, Inc.
$67.57 $85.27 $26.4B 37.61x $0.00 0% 6.10x
IVF
INVO Fertility, Inc.
$0.84 -- $12.7M -- $0.00 0% 0.02x
NMTC
NeuroOne Medical Technologies Corp.
$0.73 $2.23 $36.8M -- $0.00 0% 2.42x
NTRB
Nutriband, Inc.
$4.80 $15.00 $58.3M -- $0.00 0% 23.95x
SINT
SINTX Technologies, Inc.
$3.74 $12.25 $14.4M -- $0.00 0% 6.34x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BLFS
BioLife Solutions, Inc.
5.52% 0.495 1.69% 3.31x
DXCM
DexCom, Inc.
48.58% 1.694 9.81% 1.33x
IVF
INVO Fertility, Inc.
41.99% -0.446 10.12% 0.07x
NMTC
NeuroOne Medical Technologies Corp.
3.64% 2.039 0.6% 3.40x
NTRB
Nutriband, Inc.
3.31% 2.796 0.32% 7.07x
SINT
SINTX Technologies, Inc.
45.47% 1.079 22.94% 1.47x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BLFS
BioLife Solutions, Inc.
$17.2M -$89K -4.73% -5.11% -0.32% $2.8M
DXCM
DexCom, Inc.
$747.4M $242.5M 14.67% 30.94% 20.05% $579.4M
IVF
INVO Fertility, Inc.
$492.6K -$1.6M -188.23% -471.28% -93.08% -$1.8M
NMTC
NeuroOne Medical Technologies Corp.
$1.5M -$1.4M -83.42% -89.54% -50.02% -$1.5M
NTRB
Nutriband, Inc.
$63K -$3.9M -159.71% -164.64% -1121.15% -$1.8M
SINT
SINTX Technologies, Inc.
-$66K -$3.4M -115.95% -208.36% -1612.98% -$2.6M

BioLife Solutions, Inc. vs. Competitors

  • Which has Higher Returns BLFS or DXCM?

    DexCom, Inc. has a net margin of 2.21% compared to BioLife Solutions, Inc.'s net margin of 23.47%. BioLife Solutions, Inc.'s return on equity of -5.11% beat DexCom, Inc.'s return on equity of 30.94%.

    Company Gross Margin Earnings Per Share Invested Capital
    BLFS
    BioLife Solutions, Inc.
    61.36% $0.01 $374.4M
    DXCM
    DexCom, Inc.
    61.8% $0.70 $5.3B
  • What do Analysts Say About BLFS or DXCM?

    BioLife Solutions, Inc. has a consensus price target of $32.10, signalling upside risk potential of 28.92%. On the other hand DexCom, Inc. has an analysts' consensus of $85.27 which suggests that it could grow by 26.19%. Given that BioLife Solutions, Inc. has higher upside potential than DexCom, Inc., analysts believe BioLife Solutions, Inc. is more attractive than DexCom, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    BLFS
    BioLife Solutions, Inc.
    9 0 0
    DXCM
    DexCom, Inc.
    20 4 0
  • Is BLFS or DXCM More Risky?

    BioLife Solutions, Inc. has a beta of 1.933, which suggesting that the stock is 93.255% more volatile than S&P 500. In comparison DexCom, Inc. has a beta of 1.513, suggesting its more volatile than the S&P 500 by 51.265%.

  • Which is a Better Dividend Stock BLFS or DXCM?

    BioLife Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DexCom, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions, Inc. pays -- of its earnings as a dividend. DexCom, Inc. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BLFS or DXCM?

    BioLife Solutions, Inc. quarterly revenues are $28.1M, which are smaller than DexCom, Inc. quarterly revenues of $1.2B. BioLife Solutions, Inc.'s net income of $621K is lower than DexCom, Inc.'s net income of $283.8M. Notably, BioLife Solutions, Inc.'s price-to-earnings ratio is -- while DexCom, Inc.'s PE ratio is 37.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions, Inc. is 11.92x versus 6.10x for DexCom, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BLFS
    BioLife Solutions, Inc.
    11.92x -- $28.1M $621K
    DXCM
    DexCom, Inc.
    6.10x 37.61x $1.2B $283.8M
  • Which has Higher Returns BLFS or IVF?

    INVO Fertility, Inc. has a net margin of 2.21% compared to BioLife Solutions, Inc.'s net margin of -150.51%. BioLife Solutions, Inc.'s return on equity of -5.11% beat INVO Fertility, Inc.'s return on equity of -471.28%.

    Company Gross Margin Earnings Per Share Invested Capital
    BLFS
    BioLife Solutions, Inc.
    61.36% $0.01 $374.4M
    IVF
    INVO Fertility, Inc.
    28.04% -$6.14 $10.1M
  • What do Analysts Say About BLFS or IVF?

    BioLife Solutions, Inc. has a consensus price target of $32.10, signalling upside risk potential of 28.92%. On the other hand INVO Fertility, Inc. has an analysts' consensus of -- which suggests that it could grow by 17091.98%. Given that INVO Fertility, Inc. has higher upside potential than BioLife Solutions, Inc., analysts believe INVO Fertility, Inc. is more attractive than BioLife Solutions, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    BLFS
    BioLife Solutions, Inc.
    9 0 0
    IVF
    INVO Fertility, Inc.
    0 0 0
  • Is BLFS or IVF More Risky?

    BioLife Solutions, Inc. has a beta of 1.933, which suggesting that the stock is 93.255% more volatile than S&P 500. In comparison INVO Fertility, Inc. has a beta of 2.540, suggesting its more volatile than the S&P 500 by 153.97%.

  • Which is a Better Dividend Stock BLFS or IVF?

    BioLife Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. INVO Fertility, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions, Inc. pays -- of its earnings as a dividend. INVO Fertility, Inc. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BLFS or IVF?

    BioLife Solutions, Inc. quarterly revenues are $28.1M, which are larger than INVO Fertility, Inc. quarterly revenues of $1.8M. BioLife Solutions, Inc.'s net income of $621K is higher than INVO Fertility, Inc.'s net income of -$2.6M. Notably, BioLife Solutions, Inc.'s price-to-earnings ratio is -- while INVO Fertility, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions, Inc. is 11.92x versus 0.02x for INVO Fertility, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BLFS
    BioLife Solutions, Inc.
    11.92x -- $28.1M $621K
    IVF
    INVO Fertility, Inc.
    0.02x -- $1.8M -$2.6M
  • Which has Higher Returns BLFS or NMTC?

    NeuroOne Medical Technologies Corp. has a net margin of 2.21% compared to BioLife Solutions, Inc.'s net margin of -59.08%. BioLife Solutions, Inc.'s return on equity of -5.11% beat NeuroOne Medical Technologies Corp.'s return on equity of -89.54%.

    Company Gross Margin Earnings Per Share Invested Capital
    BLFS
    BioLife Solutions, Inc.
    61.36% $0.01 $374.4M
    NMTC
    NeuroOne Medical Technologies Corp.
    55.77% -$0.03 $7.3M
  • What do Analysts Say About BLFS or NMTC?

    BioLife Solutions, Inc. has a consensus price target of $32.10, signalling upside risk potential of 28.92%. On the other hand NeuroOne Medical Technologies Corp. has an analysts' consensus of $2.23 which suggests that it could grow by 204.92%. Given that NeuroOne Medical Technologies Corp. has higher upside potential than BioLife Solutions, Inc., analysts believe NeuroOne Medical Technologies Corp. is more attractive than BioLife Solutions, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    BLFS
    BioLife Solutions, Inc.
    9 0 0
    NMTC
    NeuroOne Medical Technologies Corp.
    1 0 0
  • Is BLFS or NMTC More Risky?

    BioLife Solutions, Inc. has a beta of 1.933, which suggesting that the stock is 93.255% more volatile than S&P 500. In comparison NeuroOne Medical Technologies Corp. has a beta of 0.703, suggesting its less volatile than the S&P 500 by 29.673%.

  • Which is a Better Dividend Stock BLFS or NMTC?

    BioLife Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroOne Medical Technologies Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions, Inc. pays -- of its earnings as a dividend. NeuroOne Medical Technologies Corp. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BLFS or NMTC?

    BioLife Solutions, Inc. quarterly revenues are $28.1M, which are larger than NeuroOne Medical Technologies Corp. quarterly revenues of $2.7M. BioLife Solutions, Inc.'s net income of $621K is higher than NeuroOne Medical Technologies Corp.'s net income of -$1.6M. Notably, BioLife Solutions, Inc.'s price-to-earnings ratio is -- while NeuroOne Medical Technologies Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions, Inc. is 11.92x versus 2.42x for NeuroOne Medical Technologies Corp.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BLFS
    BioLife Solutions, Inc.
    11.92x -- $28.1M $621K
    NMTC
    NeuroOne Medical Technologies Corp.
    2.42x -- $2.7M -$1.6M
  • Which has Higher Returns BLFS or NTRB?

    Nutriband, Inc. has a net margin of 2.21% compared to BioLife Solutions, Inc.'s net margin of -1118.87%. BioLife Solutions, Inc.'s return on equity of -5.11% beat Nutriband, Inc.'s return on equity of -164.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    BLFS
    BioLife Solutions, Inc.
    61.36% $0.01 $374.4M
    NTRB
    Nutriband, Inc.
    18.2% -$0.32 $7.8M
  • What do Analysts Say About BLFS or NTRB?

    BioLife Solutions, Inc. has a consensus price target of $32.10, signalling upside risk potential of 28.92%. On the other hand Nutriband, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 212.5%. Given that Nutriband, Inc. has higher upside potential than BioLife Solutions, Inc., analysts believe Nutriband, Inc. is more attractive than BioLife Solutions, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    BLFS
    BioLife Solutions, Inc.
    9 0 0
    NTRB
    Nutriband, Inc.
    1 0 0
  • Is BLFS or NTRB More Risky?

    BioLife Solutions, Inc. has a beta of 1.933, which suggesting that the stock is 93.255% more volatile than S&P 500. In comparison Nutriband, Inc. has a beta of 1.907, suggesting its more volatile than the S&P 500 by 90.735%.

  • Which is a Better Dividend Stock BLFS or NTRB?

    BioLife Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions, Inc. pays -- of its earnings as a dividend. Nutriband, Inc. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BLFS or NTRB?

    BioLife Solutions, Inc. quarterly revenues are $28.1M, which are larger than Nutriband, Inc. quarterly revenues of $346.1K. BioLife Solutions, Inc.'s net income of $621K is higher than Nutriband, Inc.'s net income of -$3.9M. Notably, BioLife Solutions, Inc.'s price-to-earnings ratio is -- while Nutriband, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions, Inc. is 11.92x versus 23.95x for Nutriband, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BLFS
    BioLife Solutions, Inc.
    11.92x -- $28.1M $621K
    NTRB
    Nutriband, Inc.
    23.95x -- $346.1K -$3.9M
  • Which has Higher Returns BLFS or SINT?

    SINTX Technologies, Inc. has a net margin of 2.21% compared to BioLife Solutions, Inc.'s net margin of -1701.44%. BioLife Solutions, Inc.'s return on equity of -5.11% beat SINTX Technologies, Inc.'s return on equity of -208.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    BLFS
    BioLife Solutions, Inc.
    61.36% $0.01 $374.4M
    SINT
    SINTX Technologies, Inc.
    -31.73% -$3.46 $7.5M
  • What do Analysts Say About BLFS or SINT?

    BioLife Solutions, Inc. has a consensus price target of $32.10, signalling upside risk potential of 28.92%. On the other hand SINTX Technologies, Inc. has an analysts' consensus of $12.25 which suggests that it could grow by 227.54%. Given that SINTX Technologies, Inc. has higher upside potential than BioLife Solutions, Inc., analysts believe SINTX Technologies, Inc. is more attractive than BioLife Solutions, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    BLFS
    BioLife Solutions, Inc.
    9 0 0
    SINT
    SINTX Technologies, Inc.
    2 0 0
  • Is BLFS or SINT More Risky?

    BioLife Solutions, Inc. has a beta of 1.933, which suggesting that the stock is 93.255% more volatile than S&P 500. In comparison SINTX Technologies, Inc. has a beta of 0.633, suggesting its less volatile than the S&P 500 by 36.717%.

  • Which is a Better Dividend Stock BLFS or SINT?

    BioLife Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions, Inc. pays -- of its earnings as a dividend. SINTX Technologies, Inc. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BLFS or SINT?

    BioLife Solutions, Inc. quarterly revenues are $28.1M, which are larger than SINTX Technologies, Inc. quarterly revenues of $208K. BioLife Solutions, Inc.'s net income of $621K is higher than SINTX Technologies, Inc.'s net income of -$3.5M. Notably, BioLife Solutions, Inc.'s price-to-earnings ratio is -- while SINTX Technologies, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions, Inc. is 11.92x versus 6.34x for SINTX Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BLFS
    BioLife Solutions, Inc.
    11.92x -- $28.1M $621K
    SINT
    SINTX Technologies, Inc.
    6.34x -- $208K -$3.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is DocuSign Stock Undervalued?
Is DocuSign Stock Undervalued?

Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…

Is SentinelOne Stock Undervalued?
Is SentinelOne Stock Undervalued?

Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…

Is Broadcom Stock on Sale?
Is Broadcom Stock on Sale?

Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…

Stock Ideas

Buy
59
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 65x

Buy
55
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 37x

Buy
61
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Buy
72
GLTO alert for Dec 27

Galecto, Inc. [GLTO] is up 16.92% over the past day.

Sell
20
SMX alert for Dec 27

SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.

Sell
11
CDNAF alert for Dec 27

Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock